News Center

位置：

Honors Announcement

Group News

Media Reports

The company’s brand value and brand strength rank among the top 30 in the pharmaceutical industry.

Category:

Honors Announcement

发布时间：2018-11-08

【概要描述】 Release of the 2018 China Brand Value Evaluation Results On May 9, the “2018 China Brand Value Evaluation Results” were unveiled in Shanghai at an event jointly organized by the China Brand Building Promotion Association, the Economic Daily, the China Council for the Promotion of International Trade, the China Association of Asset Appraisers, and other institutions. According to the “2018 Brand Value Evaluation Release List,” a total of 46 pharmaceutical brands from the healthcare sector made the list. Among them, our company ranked 21st with a brand strength score of 884 and a brand value of RMB 3.467 billion, firmly establishing itself as the leading domestic brand in the large-volume parenteral solutions manufacturing sector and fully demonstrating its strength in the pharmaceutical market.

Release of the 2018 China Brand Value Evaluation Results

On May 9, the “2018 China Brand Value Evaluation Information” event, jointly released by the China Brand Building Promotion Association, Economic Daily, China Council for the Promotion of International Trade, and the China Association of Asset Appraisers, among others, was held in Shanghai. According to the “2018 Brand Value Evaluation Release List,” a total of 46 pharmaceutical brands from the healthcare sector made the list. Among them, our company ranked 21st with a brand strength score of 884 and a brand value of RMB 3.467 billion, firmly establishing itself as the leading domestic brand in the large-volume parenteral solutions production segment and fully demonstrating the broad recognition the pharmaceutical market accorded to our brand.

This year’s release of China’s Brand Value Assessment results marks the fifth consecutive year that such an event has been held in China. The assessment covers four major categories: corporate brands, product brands, regional brands, and independently innovative brands, and has published top-50 rankings across multiple industries and sectors, encompassing 1,346 enterprises and 718 brands.

The eligibility criteria for this brand evaluation are quite stringent: only manufacturing enterprises that have maintained consecutive profitability over the past three years and achieved an average annual profit and tax contribution of no less than RMB 100 million are eligible for nomination. In accordance with the principle of voluntary participation, the China Brand Building Promotion Association has conducted this brand-value assessment in line with relevant standards such as ISO 10668, and will coordinate with authoritative media outlets to publicly disclose the results based on the assessment findings.

In recent years, the company has adhered to the business philosophy of “integrity as the foundation, quality-driven service to the people,” using a strengthened commitment to comprehensive quality management as the key lever to drive both product-brand and corporate-brand development, thereby forging a distinctive path of quality-brand growth that reflects the unique characteristics of Siyao. Over seven decades of relentless effort and brand-building, the company’s large-volume parenteral solutions have earned a stellar reputation in both domestic and international markets; soft-bag infusions alone account for more than 50% of China’s total market share. Its products have successfully obtained quality certifications and audits from multiple regulatory authorities, including Australia’s TGA and the Netherlands’ IDA, and are now distributed across China and 80 other countries and regions. The company has also been honored with numerous awards, such as the National Quality Product Award, Provincial Famous Brand, and Consumer Trusted Product. Moreover, the company’s “Shimen” trademark was among the first to be recognized as a well-known trademark in China’s large-volume parenteral solutions manufacturing sector. Today, the company boasts an annual production capacity of 2 billion bottles (or bags) of large-volume parenteral solutions, placing it at the forefront of the domestic industry in terms of production scale, quality standards, manufacturing technology, and brand influence. It has been ranked among the Top 100 Chinese pharmaceutical enterprises in overall strength and among the Top 10 outstanding brands in China’s chemical pharmaceutical preparations export sector, firmly establishing itself as a major national hub for the production, R&D, and export of large-volume injectable solutions.

Qu Jiguang, Chairman of the Company, stated: “We will further accelerate our internationalization efforts, with a strong focus on cultivating a portfolio of renowned brands that boast robust global competitiveness and high value-added. We will continue to expand and strengthen our national pharmaceutical brands, striving to build a comprehensive, modern, and internationally oriented pharmaceutical group. Upholding our brand philosophy of becoming a world-class enterprise that produces first-rate medicines and delivers first-rate services, we will actively promote the global reach of Chinese brands, elevate the Siyao brand to the international market, better serve human health and well-being, and establish a century-old, leading enterprise.”

Keywords:

Wang Dongfeng, Secretary of the Provincial Party Committee, presented Chairman Qu Jiguang with the Certificate of the First-Class Award for Scientific and Technological Progress.

Yin Dianshu Awarded the “Provincial May Day Labor Medal”

Wang Dongfeng, Secretary of the Provincial Party Committee, presented Chairman Qu Jiguang with the Certificate of the First-Class Award for Scientific and Technological Progress.

Yin Dianshu Awarded the “Provincial May Day Labor Medal”